Compare Amylx Pharmaceuticals Inc (AMLX) vs Skyworks Solutions Inc (SWKS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Skyworks Solutions Inc — how do they compare? Amylx Pharmaceuticals Inc trades at $17.34 (market cap $1.98B), while Skyworks Solutions Inc trades at $58.86 (market cap $9.08B). The key difference: Skyworks Solutions Inc is far larger — about 4.6× Amylx Pharmaceuticals Inc's market cap, and Skyworks Solutions Inc pays a 4.7% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | SWKS | |
|---|---|---|
Market Cap | $1.98B | $9.08B |
Sector | Health | Technology |
52-Week High | $18.70 | $83.40 |
52-Week Low | $7.64 | $52.50 |
Enterprise Value | $1.70B | $8.85B |
Dividend Yield | — | 4.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
SWKS trades at $60.36, up 0.68% on the day, with a bearish technical signal but bullish oscillators. The company reported Q1 2026 EPS of $1.15, beating estimates, and maintains a dividend. Revenue has trended down from $5.5B in 2022 to $4.1B in 2025, though net income margin remains positive at 8.93%. Recent news highlights potential in smartphone chips and AI infrastructure.
The outlook is mixed: strong analyst buy consensus (60%) and a $72.56 price target suggest upside, but declining revenue, legal investigations, and a bearish technical trend pose risks. The stock's valuation at a P/E of 25.16 appears reasonable if growth stabilizes, but investor caution is warranted amid competitive and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Skyworks Solutions Inc
Skyworks Solutions produces semiconductors for wireless handsets and other devices that are used to enable wireless connectivity. Its main products include power amplifiers, filters, switches, and integrated front-end modules that support wireless transmissions. Skyworks' customers are mostly large smartphone manufacturers, but the firm also has a growing presence in nonhandset applications such as wireless routers, medical devices, and automobiles.
Read more on SWKS →
